Fujifilm Invests USD 188 Million in New Cell Culture Media Manufacturing Facility


By Rashmi Phumatia, 26 December, 2022


FUJIFILM Corporation announced an investment of USD 188 million for establishing a cell culture media manufacturing facility in Research Triangle Park (RTP) of North Carolina, USA in November 2022. The new site would be operated by FUJIFILM Irvine Scientific, Inc., a subsidiary of FUJIFILM Corporation as well as a leading developer and manufacturer of advanced cell culture solutions for cell therapy manufacturing, life science research, bioproduction, and medical applications. The new facility is intended to ensure that the company’s subsidiary can cater to the rising demand of high-quality cell culture media solutions.

FUJIFILM Irvine Scientific has registered a significant growth over the past decade and the forecasted demand of cell culture media to support bioproduction and advanced therapies is anticipated to grow at a compound annual growth rate (CAGR) of 10%-12% through 2031. The company made the strategic decision of expanding their capacity by constructing manufacturing facilities in biotech centers throughout the world to meet the requirements of its customers. This strategy also assures a secure supply chain in line with a rapid and reliable product delivery through the development of extensive regional supply networks crucial for supporting cell and gene therapies.

Teiichi Goto, chief executive officer and president, representative director of FUJIFILM Corporation in an interview, stated that, “Fujifilm’s intensive investment in the life sciences field demonstrated our commitment of being the dedicated partner for the customers in the biopharmaceutical industry.” He also said, “We will continue to contribute towards the customers’ robust manufacturing process and the creation of novel therapies to make the world a healthier place with the support of the improved capabilities of our global manufacturing facilities for cell culture media.” Yutaka Yamaguchi, chief executive officer and chairman of FUJIFILM Irvine Scientific stated “Our customers require a rapid and reliable delivery of cell culture media for supporting their commercial production. The cell culture media produced at the North Carolina site will support in ensuring a steady supply of raw materials for cell & gene therapies, biologics, and other key medicines essential to human health.”

Land construction and development will be initiated in spring 2023 with facility operation beginning in the year 2025.
Composition of mammalian cell culture media
DESCRIPTION:
The image shows composition of mammalian cell culture media

Download Image


URL for the News


  



Latest News